Ikena Oncology amends executive’s equity vesting terms tied to pending Inmagene merger

ImageneBio, Inc.

Effective July 15, 2025, Ikena Oncology amended employment agreement with Dr. Jotin Marango, an executive officer.
Amendment provides for full acceleration of time-based equity awards if termination without cause or resignation during change in control period.
Change in control period began March 18, 2025 (initial S-4 filing for merger with Inmagene) and ends 12 months post-merger.
Accelerated vesting effective later of termination date or change in control; forfeiture of unvested portions delayed until that date.
Contemplated merger with Inmagene Biopharmaceutics was announced December 23, 2024.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.